Specifically, von Minckwitz et al. have reported that the addition of BVZ to neoadjuvant chemotherapy significantly increased the rate of pathological complete response (pCR) (14.9% chemo alone vs 18.4% chemo plus BVZ) among patients with HER2-negative early-stage breast cancer, specifically those with early stage node negative triple negative disease19. This evidence concerns the gene ERBB2 and breast cancer.